Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy
2013 ◽
Vol 8
(4)
◽
pp. 774-790
◽
Keyword(s):
2014 ◽
Vol 23
◽
pp. 1-7
◽
2020 ◽
Keyword(s):
2020 ◽
Keyword(s):